Language – Talk Bio

Bain Capital, Mitsubishi Tanabe Pharma, acquisition, Japanese pharmaceutical industry, carve-out transaction, private equity, life sciences investment

CDC Orders Retraction of Research Papers and Removes Website Content Amid New Language Restrictions

3 months ago talkbio0Tagged Centers for Disease Control and Prevention (U.S.), Feeling content, Gender, Languages, LGBTQ+, removal technique, research retraction, restrictions, Scientific Publication, Sense of identity (observable entity), Web Site

CDC, research retraction, website content removal, language restrictions, LGBTQ, gender identity, scientific publications

BIOSECURE Act Excluded from US Defense Bill, Offering Reprieve to Chinese Biotechs

5 months ago talkbio0Tagged BIOSECURE, Biotechnology, biotechs, Chinese Language, National Security, U.S.

BIOSECURE Act, Chinese biotechs, US defense bill, biotechnology supply chains, national security concerns

Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis

6 months ago talkbio0Tagged acceptance, Chinese Language, Clinical Trials, Dental Plaque, inhibitors, Innovent, interleukin-23, NDA, Phase 3, Phase 3, picankibart, Regulators (device)

Innovent Biologics, Picankibart, IL-23 inhibitors, Plaque psoriasis, Phase 3 clinical trial, Chinese regulators, NDA acceptance

Sangamo Therapeutics Aligns with FDA on Accelerated Approval Pathway for ST-920 Gene Therapy in Fabry Disease

6 months ago talkbio0Tagged Accelerated, approval pathway, Blackfoot language, Fabry Disease, gene therapy, Sangamo, ST-920, Submission, United States Food and Drug Administration

Sangamo Therapeutics, FDA, Accelerated Approval Pathway, ST-920, Fabry Disease, Gene Therapy, BLA Submission

BIOSECURE Act: Navigating Industry Implications and Future Directions

7 months ago talkbio0Tagged BIOSECURE, Biotechnology, capabilities, CDMOs, Chinese Language, Contract agreement, development aspects, Industry, Manufacture, manufacturing organizations, pharmaceutical imports, Pharmaceutical supply chain resilience, Supply chain disruptions, United States

BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience

Japanese Regulators Approve Medications from Amgen, Eli Lilly, Takeda, and Nxera

7 months ago talkbio0Tagged amgen, Drug Industry, Eli, Eli Lilly, Japanese language, Nxera, Regulators (device), regulatory, Takeda

Japanese regulators, medication approvals, Amgen, Eli Lilly, Takeda, Nxera, pharmaceutical industry, regulatory updates